A2M Pharma

A2M Pharma is a spin-off from Schwarz Pharma with the aim of developing the most promising projects of Schwarz Pharma’s former R&D pipeline that was abandoned for strategic reasons following its merger with UCB. This portfolio includes projects in neurology and pain. A2M Pharma develops these projects until clinical proof of concept which will then be out-licensed or partnered. The current lead projects focus on the treatment of Parkinson’s disease and are supported by the Michael J Fox Foundation. A small molecular modulator of lipid rafts is in preclinical development as an α-synuclein aggregation inhibitor for disease modifying treatment of Parkinson’s Disease and potential for other protein aggregation disorders. The second lead project focusses on the treatment of dyskinesias and involves a NCE for transdermal delivery.